Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer
Engelsk titel: The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients
Läs online
Författare:
Ulrik, Charlotte Suppli
Email: csulrik@dadlnet.dk
Språk: Dan
Antal referenser: 27
Dokumenttyp:
Översikt
UI-nummer: 15117765
Sammanfattning
Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews
the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single
therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has
clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation
as an important maintenance therapeutic option for some patients with COPD.